<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34864682</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2214-3602</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>2</Issue><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of neuromuscular diseases</Title><ISOAbbreviation>J Neuromuscul Dis</ISOAbbreviation></Journal><ArticleTitle>Impact of SARS-CoV-2 Infection Among Non-Invasive Ventilated ALS Patients.</ArticleTitle><Pagination><StartPage>257</StartPage><EndPage>259</EndPage><MedlinePgn>257-259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/JND-210733</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The impact of SARS-CoV-2 infection among neuromuscular diseases with respiratory involvement, including amyotrophic lateral sclerosis (ALS), is still to be elucidated.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">We aim to characterize the clinical outcome of ALS patients non-invasive ventilated (NIV), following SARS-CoV-2 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We analyzed retrospectively our patients followed regularly at our ALS clinic, from the beginning of the COVID-19 pandemic (middle March 2020) to March 2021. We included patients on NIV with a documented SARS-CoV-2 infection. We recorded demographic and clinical data, including from the acute infectious illness.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Three men with spinal-onset ALS are described, mean age of onset was 55&#xb1;9.1 years (45-61), and mean disease duration was 17.5&#xb1;15.9 months (6.1-41). All of them were wheelchair-bounded, with a mean ALSFRS-R of 15.3&#xb1;0.6 (15-16). One patient used NIV 15 hours/day, 2 between 4 to 7 hours/day, and all used assisted coughing twice daily. None had coexistent comorbidities. They were managed for SARS-CoV-2 infection as outpatients with fluticasone, bronchodilators, azithromycin and increasing frequency of assisted coughing. Supplemental oxygen (mean of 2 liters per minute) was needed in two patients, and one required NIV also during the daytime. Total recovery from SARS-CoV-2 infection was observed in all, despite being in an advanced stage of their disease, with severe respiratory involvement.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Prompt medical treatment is recommended for ALS patients with severe disease infected by SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oliveira Santos</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Physiology, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universit&#xe1;rio Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domingues</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physical Medicine and Rehabilitation, Hospital de Santa Maria&#xe1;rio Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gromicho</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universit&#xe1;rio Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universit&#xe1;rio Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Physiology, Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, Hospital de Santa Maria, Centro Hospitalar Universit&#xe1;rio Lisboa Norte, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neuromuscul Dis</MedlineTA><NlmUniqueID>101649948</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">non-invasive ventilation</Keyword><Keyword MajorTopicYN="N">respiratory complications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>5</Day><Hour>21</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34864682</ArticleId><ArticleId IdType="doi">10.3233/JND-210733</ArticleId><ArticleId IdType="pii">JND210733</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>